Scientific Sessions 2024  /  PVD: Putting Out Fires in Vascular Patients  /  Bleeding risk with non-vitamin K antagonist oral anticoagulants versus single antiplatelet therapy: A systematic review and meta-analysis of randomized controlled trials
Logo

American Heart Association

  2
  0

Final ID: MDP154

Bleeding risk with non-vitamin K antagonist oral anticoagulants versus single antiplatelet therapy: A systematic review and meta-analysis of randomized controlled trials

Abstract Body (Do not enter title and authors here): BACKGROUND
While non-vitamin K antagonist oral anticoagulants (NOACs) are more effective than single antiplatelets (mostly low-dose aspirin) at reducing stroke risk in patients with atrial fibrillation (AF), differences in bleeding risk between NOACs and single-dose antiplatelets across various populations remain unclear.

AIM
We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing bleeding outcomes of NOACs versus single antiplatelet therapy.

METHODS
We searched MEDLINE, EMBASE, and CENTRAL to June 2024 for RCTs that compared NOAC (therapeutic doses used for stroke prevention in AF patients) versus single antiplatelet therapy for a treatment duration of ≥3 months. For the meta-analyses, we used fixed-effects models and reported results as summary risk ratios (RRs). We used Risk of Bias 2 and GRADE to assess the quality and certainty of the evidence.

RESULTS
Eight RCTs with 26,194 participants were included. Mean follow-up time was 18 (±13) months. NOACs included in the studies were apixaban (4 studies), rivaroxaban (2 studies), and dabigatran (2 studies). All studies used low-dose aspirin as the comparator. When compared to aspirin, NOACs had a higher risk of major bleeding (326/13107 [2.5%] vs. 239/13087 [1.8%] events; RR 1.36 95% CI 1.15-1.60, I2=52%, 8 trials; high certainty) (Figure A), gastrointestinal bleeding (104/8803 [1.2%] vs. 74/8788 [0.8%] events; RR 1.39; 95%CI, 1.04-1.87; I2=0%; 5 trials; high certainty), and clinically relevant non-major bleeding (318/10397 [3.1%] vs. 230/10395 [2.2%] events; RR 1.38; 95%CI, 1.17-1.63; I2=16%; 5 trials; high certainty). There was no difference in the risk of intracranial hemorrhage (88/13107 [0.7%] vs. 84/13087 [0.6%] events; RR 1.04, 95%CI 0.78-1.41; I2=48%; 9 trials; high certainty) (Figure B) nor fatal bleeding (22/12412 [0.2%] vs. 28/12392 [0.2%] events; RR 0.78; 95%CI, 0.45-1.36; I2=8%; 6 trials; high certainty).

CONCLUSION
When compared to aspirin, NOACs are associated with an increased risk of major bleeding and clinically relevant non-major bleeding, but not intracranial hemorrhage. These data are important to inform patients about the risks of antithrombotic treatment.
  • Baskaran, Geethan  ( University of Toronto , Markham , Ontario , Canada )
  • Conen, David  ( Population Health Research Institute , Hamilton , Ontario , Canada )
  • Wang, Michael  ( Population Health Research Institute , Hamilton , Ontario , Canada )
  • Razeghi, Ghazal  ( McMaster University , Hamilton , Ontario , Canada )
  • Ma, Richard  ( McMaster University , Hamilton , Ontario , Canada )
  • Park, Louis  ( University of Toronto , Markham , Ontario , Canada )
  • Tannu, Manasi  ( Duke University Hospital , Durham , North Carolina , United States )
  • Devereaux, Pj  ( Population Health Research Institute , Hamilton , Ontario , Canada )
  • Mcintyre, William  ( Population Health Research Institute , Hamilton , Ontario , Canada )
  • Healey, Jeff  ( Population Health Research Institute , Hamilton , Ontario , Canada )
    • Author Disclosures:
    Geethan Baskaran: DO NOT have relevant financial relationships | David Conen: No Answer | Michael Wang: DO NOT have relevant financial relationships | Ghazal Razeghi: DO NOT have relevant financial relationships | Richard Ma: DO NOT have relevant financial relationships | Louis Park: No Answer | Manasi Tannu: No Answer | PJ Devereaux: DO have relevant financial relationships ; Research Funding (PI or named investigator):Abbott Diagnostics:Active (exists now) ; Consultant:Trimedic:Active (exists now) ; Consultant:Roche Canada:Past (completed) ; Consultant:Renibus:Active (exists now) ; Consultant:Astra Zeneca:Active (exists now) ; Consultant:Abbott Diagnostics:Past (completed) ; Other (please indicate in the box next to the company name):Philips Healthcare:Past (completed) ; Other (please indicate in the box next to the company name):CloudDX:Active (exists now) ; Research Funding (PI or named investigator):Siemens:Active (exists now) ; Research Funding (PI or named investigator):Roche Diagnostics:Active (exists now) ; Research Funding (PI or named investigator):AOP Pharma:Active (exists now) | William McIntyre: DO have relevant financial relationships ; Speaker:iRhythm:Past (completed) ; Consultant:Atricure:Active (exists now) | Jeff Healey: DO have relevant financial relationships ; Research Funding (PI or named investigator):BMS/Pfizer:Active (exists now) ; Research Funding (PI or named investigator):Boston Scientific:Active (exists now) ; Research Funding (PI or named investigator):Medtronic:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

PVD: Putting Out Fires in Vascular Patients

Saturday, 11/16/2024 , 02:50PM - 04:15PM

Moderated Digital Poster Session

More abstracts on this topic:
Anticoagulation versus Antiplatelets Across Subgroups of Embolic Stroke of Undetermined Source: A Meta-Analysis of Seven Randomized Controlled Trials

Ghannam Malik, Elkind Mitchell, Tirschwell David, Poli Sven, Kamel Hooman, Yaghi Shadi, Al-qudah Abdullah, Alshaer Qasem, Kronmal Richard, Ntaios George, Longstreth W, Furie Karen, Saver Jeffrey, Kasner Scott

Anticoagulation for the Prevention of Stroke Recurrence in Embolic Stroke of Undetermined Source: a meta-analysis

Chi Kuan Yu, Nanna, Md, Facc Michele, Nanna Michael, Song Junmin, El Zarif Talal, Varrias Dimitrios, Ntaios George, Chang Yu-cheng, Chiang Cho Han, Gershon Adam, Borkowski Pawel

More abstracts from these authors:
Blinded Randomized trial of Anticoagulation to prevent Ischemic stroke and Neurocognitive impairment in Atrial Fibrillation

Rivard Lena, Lanthier Sylvain, Massoud Fadi, Nault Isabelle, Dorian Paul, Kouz Simon, Racine Normand, Roux Jean-francois, Greiss Isabelle, Mayrand Helene, Gosselin Gilbert, Khairy Paul, Verma Atul, Khaykin Yaariv, Parkash Ratika, Sandhu Roopinder K., Conen David, Brouillette Judith, Robillard Alain, Bocti Christian, Field Thalia, Pelletier Guy, Talajic Mario, Chayer Celine, Deschaintre Yan, Manlucu Jaimie, Roussin Andre, Macle Laurent, Mondesert Blandine, Dyrda Katia, Tadros Rafik, Guerra Peter, Thibault Bernard, Tardif Jean-claude, Cadrin-tourigny Julia, Dubuc Marc, Raymond-paquin Alexandre, Aguilar Martin, Essebag Vidal, Nozza Anna, Guertin Marie-claude, Tremblay-gravel Maxime, David Louis-philippe, Roy Denis, Healey Jeff, Bherer Louis, Black Sandra, Nattel Stanley, Andrade Jason

Different but the same? STROKESTOP II, LOOP, NOAH-AFNET and ARTESIA

Healey Jeff, Svennberg Emma

4135791_File000005.jpg
4135791_File000005.jpg
You have to be authorized to contact abstract author. Please, Login
Not Available